CA2518883A1 - Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders - Google Patents
Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders Download PDFInfo
- Publication number
- CA2518883A1 CA2518883A1 CA002518883A CA2518883A CA2518883A1 CA 2518883 A1 CA2518883 A1 CA 2518883A1 CA 002518883 A CA002518883 A CA 002518883A CA 2518883 A CA2518883 A CA 2518883A CA 2518883 A1 CA2518883 A1 CA 2518883A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- delivery system
- poly
- general formula
- implants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 230000008569 process Effects 0.000 title claims abstract description 15
- 238000007920 subcutaneous administration Methods 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000001713 cholinergic effect Effects 0.000 title claims description 11
- 230000002950 deficient Effects 0.000 title claims description 6
- 239000013543 active substance Substances 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 13
- 125000003277 amino group Chemical group 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 11
- 239000011159 matrix material Substances 0.000 claims abstract description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract description 3
- 125000005843 halogen group Chemical group 0.000 claims abstract description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 2
- 239000007943 implant Substances 0.000 claims description 64
- 229920000642 polymer Polymers 0.000 claims description 34
- 239000000463 material Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 208000024827 Alzheimer disease Diseases 0.000 claims description 13
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 12
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 11
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims description 11
- 208000010877 cognitive disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- -1 poly(3-hydroxy-butyrolactone) Polymers 0.000 claims description 9
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 230000006870 function Effects 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 102000003914 Cholinesterases Human genes 0.000 claims description 5
- 108090000322 Cholinesterases Proteins 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 229930182843 D-Lactic acid Natural products 0.000 claims description 4
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims description 4
- 230000019771 cognition Effects 0.000 claims description 4
- 229940022769 d- lactic acid Drugs 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 229940048961 cholinesterase Drugs 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 230000008447 perception Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229920001519 homopolymer Polymers 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 229920006324 polyoxymethylene Polymers 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 230000002045 lasting effect Effects 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 25
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 20
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 20
- 238000001125 extrusion Methods 0.000 description 16
- 239000004005 microsphere Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 229920003178 (lactide-co-glycolide) polymer Polymers 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 239000006069 physical mixture Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 229960004373 acetylcholine Drugs 0.000 description 6
- 239000004570 mortar (masonry) Substances 0.000 description 6
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 5
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 5
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 5
- 239000000544 cholinesterase inhibitor Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 208000026139 Memory disease Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000006999 cognitive decline Effects 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000006764 neuronal dysfunction Effects 0.000 description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 239000002262 Schiff base Substances 0.000 description 3
- 150000004753 Schiff bases Chemical class 0.000 description 3
- 239000004809 Teflon Substances 0.000 description 3
- 229920006362 Teflon® Polymers 0.000 description 3
- 230000009460 calcium influx Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000003492 excitotoxic effect Effects 0.000 description 3
- 231100000063 excitotoxicity Toxicity 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000003517 fume Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 230000006984 memory degeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- ZRJBHWIHUMBLCN-MEBBXXQBSA-N (-)-Huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-MEBBXXQBSA-N 0.000 description 2
- 102100033639 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 2
- 0 CCNC(C(*)**)C(C(C)*C)N Chemical compound CCNC(C(*)**)C(C(C)*C)N 0.000 description 2
- 102100032404 Cholinesterase Human genes 0.000 description 2
- 206010013496 Disturbance in attention Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001090156 Huperzia serrata Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007966 viscous suspension Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241000195947 Lycopodium Species 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 208000009973 brain hypoxia - ischemia Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 238000012978 minimally invasive surgical procedure Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Percussion Or Vibration Massage (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB0300942 | 2003-03-14 | ||
| IBPCT/IB03/00942 | 2003-03-14 | ||
| IB0304945 | 2003-11-05 | ||
| IBPCT/IB03/04945 | 2003-11-05 | ||
| PCT/IB2004/000734 WO2004080436A1 (en) | 2003-03-14 | 2004-03-15 | Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2518883A1 true CA2518883A1 (en) | 2004-09-23 |
Family
ID=32992641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002518883A Abandoned CA2518883A1 (en) | 2003-03-14 | 2004-03-15 | Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20070059369A1 (enExample) |
| EP (2) | EP1603532B1 (enExample) |
| JP (1) | JP2006520378A (enExample) |
| KR (1) | KR20060023111A (enExample) |
| AT (1) | ATE404170T1 (enExample) |
| AU (1) | AU2004218896B2 (enExample) |
| BR (1) | BRPI0407818A (enExample) |
| CA (1) | CA2518883A1 (enExample) |
| CY (1) | CY1108482T1 (enExample) |
| DE (1) | DE602004015744D1 (enExample) |
| DK (1) | DK1603532T3 (enExample) |
| EA (1) | EA011169B1 (enExample) |
| ES (1) | ES2312981T3 (enExample) |
| IL (1) | IL170759A (enExample) |
| IS (1) | IS8067A (enExample) |
| MX (1) | MXPA05009626A (enExample) |
| NO (1) | NO20054258L (enExample) |
| NZ (1) | NZ542459A (enExample) |
| PL (1) | PL1603532T3 (enExample) |
| PT (1) | PT1603532E (enExample) |
| SI (1) | SI1603532T1 (enExample) |
| UA (1) | UA82226C2 (enExample) |
| WO (1) | WO2004080436A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2432556T3 (es) | 2004-08-04 | 2013-12-04 | Evonik Corporation | Métodos para fabricar dispositivos de suministro y sus dispositivos |
| US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| EP2222281B1 (en) | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| US8956636B2 (en) * | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Methods and compositions for treating postoperative pain comprosing ketorolac |
| WO2011132157A1 (en) | 2010-04-22 | 2011-10-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Oral sustained release formulation of huperzine a |
| WO2013173096A2 (en) * | 2012-05-18 | 2013-11-21 | Insero Health Inc. | Conjugates of huperzine and analogs thereof |
| KR101811797B1 (ko) * | 2013-04-03 | 2017-12-22 | 동국제약 주식회사 | 도네페질을 포함하는 비경구투여용 약제학적 조성물 |
| JP7111375B2 (ja) * | 2017-10-19 | 2022-08-02 | 株式会社佐藤園 | 学習記憶能力増強組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106979A (en) * | 1989-02-21 | 1992-04-21 | University Of Pittsburgh | Method for the synthesis of huperzine A and analogs thereof and compounds useful therein |
| CN1125725A (zh) * | 1994-12-28 | 1996-07-03 | 中国科学院上海药物研究所 | 一类海克林碱衍生物及它的用途 |
| FR2756493B1 (fr) * | 1996-12-02 | 2001-04-13 | Delab | Dispositif d'administration locale de formulations solides ou semi-solides |
| US6352715B1 (en) | 1998-02-19 | 2002-03-05 | Sagittarius Life Science Corp | Transdermal rate-controlled delivery of Huperzine A for treatment of alzheimer's disease |
| US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| CN1279065A (zh) | 1999-07-06 | 2001-01-10 | 青岛科达生物工程有限公司 | 一种治疗记忆障碍和老年痴呆的药物组合物 |
| CN1194688C (zh) * | 2001-07-03 | 2005-03-30 | 山东绿叶制药股份有限公司 | 石杉碱甲及其衍生物或其盐的注射用缓释微球及其制备方法 |
| CN1383824A (zh) | 2002-05-21 | 2002-12-11 | 浙江省医学科学院 | 石杉碱鼻腔给药制剂 |
-
2004
- 2004-03-15 ES ES04720662T patent/ES2312981T3/es not_active Expired - Lifetime
- 2004-03-15 SI SI200430920T patent/SI1603532T1/sl unknown
- 2004-03-15 JP JP2006506340A patent/JP2006520378A/ja active Pending
- 2004-03-15 EA EA200501433A patent/EA011169B1/ru not_active IP Right Cessation
- 2004-03-15 KR KR1020057016999A patent/KR20060023111A/ko not_active Ceased
- 2004-03-15 BR BRPI0407818-7A patent/BRPI0407818A/pt not_active IP Right Cessation
- 2004-03-15 EP EP04720662A patent/EP1603532B1/en not_active Expired - Lifetime
- 2004-03-15 UA UAA200509681A patent/UA82226C2/uk unknown
- 2004-03-15 AU AU2004218896A patent/AU2004218896B2/en not_active Ceased
- 2004-03-15 DE DE602004015744T patent/DE602004015744D1/de not_active Expired - Lifetime
- 2004-03-15 DK DK04720662T patent/DK1603532T3/da active
- 2004-03-15 EP EP08159962A patent/EP1977735A1/en not_active Withdrawn
- 2004-03-15 WO PCT/IB2004/000734 patent/WO2004080436A1/en not_active Ceased
- 2004-03-15 PT PT04720662T patent/PT1603532E/pt unknown
- 2004-03-15 CA CA002518883A patent/CA2518883A1/en not_active Abandoned
- 2004-03-15 US US10/549,167 patent/US20070059369A1/en not_active Abandoned
- 2004-03-15 MX MXPA05009626A patent/MXPA05009626A/es active IP Right Grant
- 2004-03-15 NZ NZ542459A patent/NZ542459A/en unknown
- 2004-03-15 AT AT04720662T patent/ATE404170T1/de not_active IP Right Cessation
- 2004-03-15 PL PL04720662T patent/PL1603532T3/pl unknown
-
2005
- 2005-09-08 IL IL170759A patent/IL170759A/en not_active IP Right Cessation
- 2005-09-15 NO NO20054258A patent/NO20054258L/no not_active Application Discontinuation
- 2005-10-11 IS IS8067A patent/IS8067A/is unknown
-
2008
- 2008-11-06 CY CY20081101257T patent/CY1108482T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL170759A (en) | 2010-06-16 |
| EA011169B1 (ru) | 2009-02-27 |
| EP1977735A1 (en) | 2008-10-08 |
| EP1603532A1 (en) | 2005-12-14 |
| DK1603532T3 (da) | 2008-12-08 |
| AU2004218896A1 (en) | 2004-09-23 |
| HK1089085A1 (zh) | 2006-11-24 |
| ES2312981T3 (es) | 2009-03-01 |
| NZ542459A (en) | 2008-12-24 |
| AU2004218896B2 (en) | 2010-04-01 |
| SI1603532T1 (sl) | 2009-02-28 |
| DE602004015744D1 (de) | 2008-09-25 |
| IS8067A (is) | 2005-10-11 |
| US20070059369A1 (en) | 2007-03-15 |
| EA200501433A1 (ru) | 2006-02-24 |
| PL1603532T3 (pl) | 2009-02-27 |
| CY1108482T1 (el) | 2014-04-09 |
| NO20054258D0 (no) | 2005-09-15 |
| WO2004080436A1 (en) | 2004-09-23 |
| MXPA05009626A (es) | 2005-10-18 |
| NO20054258L (no) | 2005-11-24 |
| EP1603532B1 (en) | 2008-08-13 |
| PT1603532E (pt) | 2008-11-20 |
| ATE404170T1 (de) | 2008-08-15 |
| JP2006520378A (ja) | 2006-09-07 |
| BRPI0407818A (pt) | 2006-02-14 |
| KR20060023111A (ko) | 2006-03-13 |
| UA82226C2 (uk) | 2008-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7090299B2 (ja) | ドネペジルを含有するマイクロニードル経皮パッチ | |
| AU2005229543B2 (en) | Use of an NMDA receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity | |
| MXPA03011314A (es) | Formulacion farmaceutica para la administracion eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina y sus derivados y pro-farmacos de los mismos. | |
| TW202302094A (zh) | 用於治療激躁之方法及組合物 | |
| US6277393B1 (en) | Systemic and/or local (topical) application of tetracycline and/or tetracycline derivative(s) for treating, suppressing and preventing of cerebrovascular diseases, traumas and damages of nervous system | |
| EP1154795B1 (en) | Means for treating and diagnosing restless legs syndrome | |
| JP2011515485A (ja) | ロフェキシジンを経粘膜送達するための組成物およびその方法 | |
| EP1603532B1 (en) | Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders | |
| WO2008067549A2 (en) | Stabilized zolpidem pharmaceutical compositions | |
| WO2021108801A2 (en) | Long acting nmda antagonists | |
| DE202006019887U1 (de) | Medikament zur Behandlung von viszeralem Schmerz | |
| EP1850836B1 (de) | Medikamentöse kombinationsbehandlung | |
| DE10338544B4 (de) | Buccale Formulierungen des Galanthamins und deren Anwendungen | |
| ZA200507367B (en) | Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders | |
| RU2476209C1 (ru) | Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов | |
| EP1368023B1 (de) | Verwendung von buprenorphin zur therapie der harninkontinenz | |
| HK1089085B (en) | Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders | |
| WO2022175977A1 (en) | A biodegradable implant composition and process for long term delivery of buprenorphine and use thereof | |
| CN108601780A (zh) | 可注射组合物及治疗躯体成瘾的方法 | |
| EP3299010A1 (de) | Orale darreichungsform | |
| DE10301930A1 (de) | Verfahren zur medikamentösen therapeutischen oder prophylaktischen Behandlung | |
| WO2019166098A1 (de) | Orale darreichungsform mit theobrominfreiem kakao | |
| HK1261690A1 (en) | Injectable composition and a method of treatment of the physical addiction | |
| KR101151342B1 (ko) | 에페리손 함유 필름코팅정제, 및 이의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |